Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | IO Biotech erlangt Nasdaq-Konformität nach Erholung des Gebotspreises | 2 | Investing.com Deutsch | ||
Mi | IO Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
IO BIOTECH Aktie jetzt für 0€ handeln | |||||
23.05. | IO Biotech files for the sale of up to 5.6M shares of common stock for holders | 16 | Seeking Alpha | ||
14.05. | IO Biotech, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
14.05. | IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights | 281 | GlobeNewswire (Europe) | Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still expected to readout in third quarter of 2025Data... ► Artikel lesen | |
14.05. | IO Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
30.04. | IO Biotech, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
26.04. | IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025 | 1 | GlobeNewswire (USA) | ||
25.04. | IO Biotech präsentiert vielversprechende präklinische Daten zu Impfstoffkandidaten | 2 | Investing.com Deutsch | ||
25.04. | IO Biotech unveils promising vaccine preclinical data | 1 | Investing.com | ||
25.04. | IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170 | 2 | GlobeNewswire (USA) | ||
07.04. | IO Biotech, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
31.03. | IO Biotech, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
25.03. | IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting | 2 | GlobeNewswire (USA) | ||
05.03. | IO Biotech stock retains Buy rating, $12 target at H.C. Wainwright | 12 | Investing.com | ||
04.03. | IO Biotech on track with cancer vaccine BLA for 2025 | 3 | Investing.com | ||
04.03. | IO Biotech auf Kurs für Krebsimpfstoff-Zulassungsantrag bis 2025 | 7 | Investing.com Deutsch | ||
04.03. | IO Biotech Reports 2024 Business Highlights | 166 | GlobeNewswire (Europe) | Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment... ► Artikel lesen | |
04.03. | IO Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
04.02. | IO Biotech advances cancer vaccine candidate IO112 | 3 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PALATIN TECHNOLOGIES | 0,079 | -0,13 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
BIOXXMED | 0,410 | -0,49 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
VIVOSIM LABS | 1,570 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
OCUGEN | 0,779 | +0,85 % | Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST-Modifier Gene Therapy for the Treatment of Stargardt Disease | MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
BIO-GATE | 1,070 | 0,00 % | EQS-Adhoc: Bio-Gate AG: Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | EQS-Ad-hoc: Bio-Gate AG / Schlagwort(e): Kapitalmaßnahme/Kapitalmaßnahme
Bio-Gate AG beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts
03.06.2025... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,522 | +5,03 % | Defence Therapeutics Inc.: Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub | Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced... ► Artikel lesen | |
VAXART | 0,341 | -3,78 % | Vaxart, Inc.: Vaxart Announces Adjournment of Annual Meeting of Stockholders | ||
BURCON NUTRASCIENCE | 0,063 | -8,99 % | Burcon NutraScience Corporation: Burcon to Participate in 2025 Canadian Climate Investor Conference | Vancouver, British Columbia--(Newsfile Corp. - May 28, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
CELLECTAR BIOSCIENCES | 0,454 | +11,27 % | Cellectar +147%: Ich nehme die Gewinne mit! | Meine Spekulation geht auf: Cellectar Biosciences (WKN: A3DQSD) knallt heute in der Spitze um bis zu +147% durch die Decke, nachdem ich im März ein großes Comeback der Aktie in Aussicht gestellt hatte.... ► Artikel lesen | |
AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market | OCALA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. ("AIM" or the "Company") (OTC Pink: AIMI) - an immuno-pharma company focused on the research and development of therapeutics to... ► Artikel lesen | |
IMMUNIC | 0,699 | +3,25 % | Immunic sammelt 65 Millionen Dollar ein - Aktie reagiert | Immunic meldet für die erste Tranche einer Kapitalmaßnahme einen Bruttoerlös von rund 65 Millionen Dollar. Das Biotech-Unternehmen platzierte im Rahmen eines öffentlichen Angebots vorfinanzierte Aktien-Warrants... ► Artikel lesen | |
T2 BIOSYSTEMS | 0,105 | -3,67 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
CEL-SCI | 2,440 | 0,00 % | Pre-market Movers: Navitas Semiconductor, Longevity Health, CEL-SCI, Hyperscale Data, Sunrun | PHILADELPHIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 06.35 A.M. ET).In the Green Navitas Semiconductor Corporation (NVTS) is... ► Artikel lesen |